Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication

被引:20
|
作者
Taskin, Orhun Cig [1 ]
Clarke, Callisia N. [2 ]
Erkan, Mert [3 ,4 ]
Tsai, Susan [2 ]
Evans, Douglas B. [2 ]
Adsay, Volkan [1 ]
机构
[1] Koc Univ Hosp, Dept Pathol, Davutpasa Caddesi 4, TR-34010 Istanbul, Turkey
[2] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA
[3] Koc Univ Hosp, Dept Surg, Istanbul, Turkey
[4] Koc Univ, Res Ctr Translat Med, Istanbul, Turkey
关键词
Pancreas; neuroendocrine neoplasm; tumor; carcinoma; pathology; terminology; classification; prognosis; WHO; 2019; KI67 PROLIFERATIVE INDEX; CLINICOPATHOLOGICAL ANALYSIS; ENDOCRINE NEOPLASMS; HIGH-GRADE; GASTROENTEROPANCREATIC SYSTEM; CONSENSUS GUIDELINES; LABELING INDEX; CELL-CARCINOMA; TUMORS; EXPRESSION;
D O I
10.21037/jgo.2020.03.07
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Significant improvements have taken place in our understanding of classification neuroendocrine neoplasms of the pancreas in the past decade. "These are now regarded in three entirely separate categories: (I) neuroendocrine tumors (PanNETs) are by definition well differentiated, the pancreatic counterpart of carcinoids; (II) neuroendocrine carcinomas, which are poorly differentiated (PDNEC), the pancreatic examples of small cell carcinomas or large cell neuroendocrine carcinomas; (III) other neoplasms that have neuroendocrine differentiation or a distinct neuroendocrine component. PanNETs are by far the most common. They are now regarded as malignancies (albeit often curable when low grade and low stage) with the exception of minute incidental proliferations (tumorlets, or dysplastic-like changes) seen in the setting of some syndromes like MEN. PanNETs are staged based on their size, and for small T1 tumors, watchful waiting is now being considered, although these tumors are also known to show about 10% metastatic rate and/or progression, creating concerns about this approach. PanNETs are graded into 3, based on the proliferative activity, mostly based on the Ki-67 index, and also partly mitotic activity, although the latter seldom if ever is the determinant of the final grade. Neuroendocrine neoplasms with well differentiated morphology but Ki-67 >20% are now regarded as Pa.nNFT Grade 3 (G3); they have been shown to have a prognosis significantly worse than lesser grade PanNETs but still incomparably better than frank PDNECs, the latter typically has Ki-67 >50% (often much higher) and require platinum-based chemotherapy. There are also cases that are ambiguous between PanNET-G3 and PDNEC, and very rarely transformation of the former to the latter appears to occur. For low grade (G 1/G2) PanNETs, more refined criteria to further prognosticate this group are needed. Morphologic variants being recognized may bring new perspectives to this group.
引用
收藏
页码:548 / 558
页数:11
相关论文
共 50 条
  • [1] Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms
    Teo, Roxanne Y. A.
    Teo, Timothy Z.
    Tai, David W. M.
    Tan, Damien M.
    Ong, Simon
    Goh, Brian K. P.
    SURGERY, 2019, 165 (04) : 672 - 685
  • [2] Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies
    Paik, Woo Hyun
    Lee, Kyong Joo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (01)
  • [3] Terminology and Classification of Neuroendocrine Neoplasms of the Larynx
    Lewis, James S., Jr.
    Ferlito, Alfio
    Gnepp, Douglas R.
    Rinaldo, Alessandra
    Devaney, Kenneth O.
    Silver, Carl E.
    Travis, William D.
    LARYNGOSCOPE, 2011, 121 (06): : 1187 - 1193
  • [4] TERMINOLOGY AND CLASSIFICATION OF NEUROENDOCRINE NEOPLASMS OF THE LARYNX
    FERLITO, A
    ROSAI, J
    ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 1991, 53 (04): : 185 - 187
  • [5] Current controversies in pancreatic cystic neoplasms
    Walsh, R. Matthew
    AMERICAN JOURNAL OF SURGERY, 2017, 213 (03): : 443 - 447
  • [6] Recent advances and current controversies in lung neuroendocrine neoplasms*
    Metovic, Jasna
    Bianchi, Fabrizio
    Rossi, Giulio
    Barella, Marco
    Sonzogni, Angelica
    Harari, Sergio
    Papotti, Mauro
    Pelosi, Giuseppe
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2021, 38 (05) : 90 - 97
  • [7] Proteotranscriptomic Classification and Characterization of Pancreatic Neuroendocrine Neoplasms
    Yang, K.
    Kalloger, S.
    Aird, J.
    Lee, M.
    Rushton, C.
    Miko, S. E. Spencer
    Mungall, K.
    Mungall, A.
    Colborne, S.
    Morin, R.
    Loree, J.
    Marra, M.
    Renouf, D.
    Morin, G.
    Schaeffer, D.
    Gorski, S.
    PANCREAS, 2021, 50 (03) : 441 - 441
  • [8] Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms
    Yang, Kevin C.
    Kalloger, Steve E.
    Aird, John J.
    Lee, Michael K. C.
    Rushton, Christopher
    Mungall, Karen L.
    Mungall, Andrew J.
    Gao, Dongxia
    Chow, Christine
    Xu, Jing
    Karasinska, Joanna M.
    Colborne, Shane
    Jones, Steven J. M.
    Schrader, Joerg
    Morin, Ryan D.
    Loree, Jonathan M.
    Marra, Marco A.
    Renouf, Daniel J.
    Morin, Gregg B.
    Schaeffer, David F.
    Gorski, Sharon M.
    CELL REPORTS, 2021, 37 (02):
  • [9] Current update on imaging for pancreatic neuroendocrine neoplasms
    Segaran, Nicole
    Devine, Catherine
    Wang, Mindy
    Ganeshan, Dhakshinamoorthy
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (10): : 897 - 911
  • [10] Validation and Comparison between Current Prognostication Systems for Pancreatic Neuroendocrine Neoplasms: Single Institution Experience with 176 Patients
    Goh, B.
    Teo, R.
    Tai, D.
    Allen, J.
    Lim, T.
    Hwang, J. S.
    Tan, D.
    Lee, S. Y.
    Chan, C. Y.
    Cheow, P. C.
    Chow, P.
    Ooi, L.
    Chung, A.
    Ong, S. Y.
    NEUROENDOCRINOLOGY, 2017, 105 : 76 - 76